Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin
Romidepsin, also known as NSC630176, FR901228, FK-228, FR-901228, depsipeptide, or Istodax®, is a natural molecule produced by the Chromobacterium violaceum bacterium that has been approved for its anti-cancer effect. This compound is a selective histone deacetylase (HDAC) inhibitor, which modifies...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
|
Subjects: | |
Online Access: | http://eprints.sunway.edu.my/2710/1/Long%20Chiau%20Ming_Molecular%20mechanistic%20pathways%20underlying%20the%20anticancer.pdf http://eprints.sunway.edu.my/2710/ https://doi.org/10.1016/j.biopha.2023.114774 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.sunway.eprints.2710 |
---|---|
record_format |
eprints |
spelling |
my.sunway.eprints.27102024-07-02T00:07:02Z http://eprints.sunway.edu.my/2710/ Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin El Omari, Nasreddine Lee, Learn-Han Bakrim, Saad Makeen, Hafiz A Alhazmi, Hassan A Mohan, Syam Khalid, Asaad Long, Chiau Ming * Bouyahya, Abdelhakim QH Natural history QP Physiology RC Internal medicine RS Pharmacy and materia medica Romidepsin, also known as NSC630176, FR901228, FK-228, FR-901228, depsipeptide, or Istodax®, is a natural molecule produced by the Chromobacterium violaceum bacterium that has been approved for its anti-cancer effect. This compound is a selective histone deacetylase (HDAC) inhibitor, which modifies histones and epigenetic pathways. An imbalance between HDAC and histone acetyltransferase can lead to the down-regulation of regulatory genes, resulting in tumorigenesis. Inhibition of HDACs by romidepsin indirectly contributes to the anticancer therapeutic effect by causing the accumulation of acetylated histones, restoring normal gene expression in cancer cells, and promoting alternative pathways, including the immune response, p53/p21 signaling cascades, cleaved caspases, poly (ADP-ribose) polymerase (PARP), and other events. Secondary pathways mediate the therapeutic action of romidepsin by disrupting the endoplasmic reticulum and proteasome and/or aggresome, arresting the cell cycle, inducing intrinsic and extrinsic apoptosis, inhibiting angiogenesis, and modifying the tumor microenvironment. This review aimed to highlight the specific molecular mechanisms responsible for HDAC inhibition by romidepsin. A more detailed understanding of these mechanisms can significantly improve the understanding of cancer cell disorders and pave the way for new therapeutic approaches using targeted therapy. Elsevier Article PeerReviewed text en cc_by_nc_nd_4 http://eprints.sunway.edu.my/2710/1/Long%20Chiau%20Ming_Molecular%20mechanistic%20pathways%20underlying%20the%20anticancer.pdf El Omari, Nasreddine and Lee, Learn-Han and Bakrim, Saad and Makeen, Hafiz A and Alhazmi, Hassan A and Mohan, Syam and Khalid, Asaad and Long, Chiau Ming * and Bouyahya, Abdelhakim Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin. Biomedicine and Pharmacotherapy, 164. ISSN 0753-3322 https://doi.org/10.1016/j.biopha.2023.114774 10.1016/j.biopha.2023.114774 |
institution |
Sunway University |
building |
Sunway Campus Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Sunway University |
content_source |
Sunway Institutional Repository |
url_provider |
http://eprints.sunway.edu.my/ |
language |
English |
topic |
QH Natural history QP Physiology RC Internal medicine RS Pharmacy and materia medica |
spellingShingle |
QH Natural history QP Physiology RC Internal medicine RS Pharmacy and materia medica El Omari, Nasreddine Lee, Learn-Han Bakrim, Saad Makeen, Hafiz A Alhazmi, Hassan A Mohan, Syam Khalid, Asaad Long, Chiau Ming * Bouyahya, Abdelhakim Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin |
description |
Romidepsin, also known as NSC630176, FR901228, FK-228, FR-901228, depsipeptide, or Istodax®, is a natural molecule produced by the Chromobacterium violaceum bacterium that has been approved for its anti-cancer effect. This compound is a selective histone deacetylase (HDAC) inhibitor, which modifies histones and epigenetic pathways. An imbalance between HDAC and histone acetyltransferase can lead to the down-regulation of regulatory genes, resulting in tumorigenesis. Inhibition of HDACs by romidepsin indirectly contributes to the anticancer therapeutic effect by causing the accumulation of acetylated histones, restoring normal gene expression in cancer cells, and promoting alternative pathways, including the immune response, p53/p21 signaling cascades, cleaved caspases, poly (ADP-ribose) polymerase (PARP), and other events. Secondary pathways mediate the therapeutic action of romidepsin by disrupting the endoplasmic reticulum and proteasome and/or aggresome, arresting the cell cycle, inducing intrinsic and extrinsic apoptosis, inhibiting angiogenesis, and modifying the tumor microenvironment. This review aimed to highlight the specific molecular mechanisms responsible for HDAC inhibition by romidepsin. A more detailed understanding of these mechanisms can significantly improve the understanding of cancer cell disorders and pave the way for new therapeutic approaches using targeted therapy. |
format |
Article |
author |
El Omari, Nasreddine Lee, Learn-Han Bakrim, Saad Makeen, Hafiz A Alhazmi, Hassan A Mohan, Syam Khalid, Asaad Long, Chiau Ming * Bouyahya, Abdelhakim |
author_facet |
El Omari, Nasreddine Lee, Learn-Han Bakrim, Saad Makeen, Hafiz A Alhazmi, Hassan A Mohan, Syam Khalid, Asaad Long, Chiau Ming * Bouyahya, Abdelhakim |
author_sort |
El Omari, Nasreddine |
title |
Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin |
title_short |
Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin |
title_full |
Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin |
title_fullStr |
Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin |
title_full_unstemmed |
Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin |
title_sort |
molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin |
publisher |
Elsevier |
url |
http://eprints.sunway.edu.my/2710/1/Long%20Chiau%20Ming_Molecular%20mechanistic%20pathways%20underlying%20the%20anticancer.pdf http://eprints.sunway.edu.my/2710/ https://doi.org/10.1016/j.biopha.2023.114774 |
_version_ |
1804069661108600832 |
score |
13.19449 |